PDCD1 and colorectal carcinoma: An ongoing phase II study (NCT05731726) is investigating the role of celecoxib as part of a neoadjuvant treatment regimen combined with PD-1 monoclonal antibody and chemotherapy in locally advanced CRC patients with the pMMR/MSS phenotype.